
Roche’s Gazyva/Gazyvaro has been approved by the FDA for adult patients with primary membranous nephropathy (pMN) who are at risk of disease progression, to induce remission of proteinuria.
PMN is a chronic autoimmune disease that can lead to kidney failure, with proteinuria, characterised by high urine protein levels. a key indicator of kidney damage.
Gazyva/Gazyvaro is the first and only therapy to receive FDA approval for this disease, having previously been granted Breakthrough Therapy Designation.
“The FDA approval of Gazyva/Gazyvaro represents an important step forward for people living with primary membranous nephropathy, where targeting B cells addresses a critical underlying driver of disease,” said Levi Garraway, Roche’s Chief Medical Officer and Head of Global Product Development. “With Gazyva/Gazyvaro, we are turning decades of specialised antibody engineering into tangible outcomes for patients with immune-mediated kidney diseases. By achieving significantly higher complete remission rates compared to tacrolimus, Gazyva/Gazyvaro offers a more effective approach to help achieve durable disease control.”
The approval is based on positive results from the phase 3 MAJESTY study. The trial met its primary endpoint, with 36.1% of adults achieving complete remission (CR) of proteinuria at two years (104 weeks) with Gazyva/Gazyvaro versus 5.7% with tacrolimus. Key secondary endpoints showed that Gazyva/Gazyvaro was superior to tacrolimus in achieving overall remission (complete or partial remission) at week 104 and complete remission at week 76. No new safety signals were identified.
pMN is a rare, chronic autoimmune condition that causes potentially irreversible kidney damage and can lead to kidney failure. People living with pMN often experience fatigue, oedema (swelling) and significant emotional and social challenges that deeply affect both patients and their families. Beyond the individual impact, pMN places a substantial burden on healthcare systems. Achieving complete remission is important to help maintain kidney function and delay or prevent the onset of serious and potentially fatal complications.
“pMN can lead to debilitating physical and psychological symptoms that place a heavy burden on patients, families and healthcare systems alike,” said Teresa Graham, CEO, Roche Pharmaceuticals. “This first-ever FDA approval delivers an important targeted treatment option for the pMN community and expands how many people may benefit from Gazyva/Gazyvaro across multiple severe immune-mediated kidney diseases.”
MAJESTY data were featured at the 63rd European Renal Association (ERA) Congress in June 2026 as a late-breaking oral presentation and published in the New England Journal of Medicine (NEJM). Data are also being submitted to other global health authorities, including the European Medicines Agency.




